KLRK1 and neoplasm: Additionally, a bispecific anti-NKG2DxHER2 antibody that simultaneously engages HER2 on tumor cells and NKG2D on NK cells induces cytotoxicity of unstimulated NK cells in a tumor-specific manner, regardless of their apparent affinities and epitopes (49).